find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
33
Clinical Trials
Multiple Myeloma
Phase I/II
Accepting Patients
nct/study# NCT02773030 / CC-220-MM-001
A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study To Determine The Maximum Tolerated Dose, Assess The Safety, Tolerability, Pharmacokinetics And Efficacy Of CC-220 As Monotherapy And In Combination With Other Treatments In Subjects With Multiple Myeloma
Learn More
Multiple Myeloma
Phase 1/2
Active
nct/study# NA / CP-NEXI-002-01
A Phase 1 / 2 Study To Evaluate The Safety And Tolerability Of Adoptively Transferred Autologous T Cells In Patients With Relapsed Refractory Multiple Myeloma
Learn More
Multiple Myeloma
NA
Active
nct/study# NA / 2021-0704
Safety Of Switching From Intravenous Daratumumab To Subcutaneous Daratumumab In Patients With Multiple Myeloma
Learn More
Multiple Myeloma
Phase I/II
Accepting Patients
nct/study# NCT03288493 / P-BCMA-101-001
Open-Label, Multicenter, Phase 1 Study To Assess The Safety Of P BCMA-101 In Subjects With Relapsed / Refractory Multiple Myeloma (MM) Followed By A Phase 2 Assessment Of Response And Safety (PRIME)
Learn More
Multiple Myeloma
NA
Accepting Patients
nct/study# NCT02911571 / PROMMIS
Prospective Observational Multiple Myeloma Impact Study Prospective Multicenter Study To Measure The Impact Of Mmprofiler On Treatment Intention In Active Multiple Myeloma Patients
Learn More
Multiple Myeloma
Phase I
Accepting Patients
nct/study# NCT04436029 / DC11B
Descartes-11 Consolidation Treatment In Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.